GEN - Genetic Engineering and Biotechnology News2d
Organon Acquires Commercialized Biosimilar to ACTEMRA from Biogen
Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...
GlobalData on MSN5d
Organon acquires Actemra biosimilar’s US rights from Biogen
Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.
Organon buys rights to Biogen’s biosimilar targeting Roche’s Actemra
Organon (NYSE:OGN) announced Tuesday the acquisition of regulatory and commercial rights linked to Tofidence, a biosimilar ...
pharmaphorum3y
Actemra shortage spills over to include Sanofi's rival Kevzara
Roche's Actemra has been in high demand since its value in treating severe COVID-19 was established, leading to shortages. Now, Sanofi's rival therapy Kevzara has also been hit by supply constraints.
pharmaphorum8d
Roche's Actemra cuts chances of COVID-19 ventilator use in phase 3 trial
Roche’s Actemra may help fight pandemic after all with phase 3 trial results showing it cut the chances of COVID-19 patients, mainly from higher risk minority ethnic backgrounds with pneumonia ...
Managed Healthcare Executive5d
Organon Expands Biosimilar Portfolio With Tofidence Acquisition
Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...
Seeking Alpha6d
Organon buys rights to Biogen’s biosimilar targeting Roche’s Actemra
arthritis drug Actemra. Biogen (NASDAQ:BIIB), which obtained regulatory and commercial rights to Tofidence from the Chinese biotech Bio-Thera Solutions in 2021, launched the monoclonal antibody ...